Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063606 · ClinicalTrials.gov registry record · Phase 2
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
A Phase 2 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03063606 is a Phase 2 study of Obesity and Binge-Eating Disorder that has completed, run by Yale University. The registered enrollment target is 31 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03063606, a Phase 2 study of Obesity and Binge-Eating Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the effectiveness of cognitive-behavioral therapy as a specialist treatment for binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, cognitive-behavioral therapy augments on-going blinded pharmacotherapy (either naltrexone/bupropion or placebo), compared with no additional behavioral treatment .
Conditions Studied
Interventions
- BEHAVIORAL Cognitive-Behavioral Therapy (CBT)
- DRUG NB Medication (on-going from acute treatment)
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063606
The ClinicalTrials.gov registry entry for NCT03063606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Cognitive-Behavioral Therapy (CBT) is the first listed.
NCT03063606 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03063606 about?
NCT03063606 is a clinical study titled "Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment". This study will test the effectiveness of cognitive-behavioral therapy as a specialist treatment for binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, cognitive-behavioral therapy augments on-going blinded pharmaco...
What is the current status of trial NCT03063606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2017-09-05. Estimated completion is 2022-12-16.
What conditions does trial NCT03063606 study?
This clinical trial studies the following conditions: Obesity, Binge-Eating Disorder.
What interventions are being tested in trial NCT03063606?
The interventions under investigation include: Cognitive-Behavioral Therapy (CBT) (BEHAVIORAL), NB Medication (on-going from acute treatment) (DRUG).
Who is sponsoring clinical trial NCT03063606?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03063606 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.